An Open Label Phase I Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV

Trial Profile

An Open Label Phase I Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jan 2015

At a glance

  • Drugs Nintedanib (Primary) ; Carboplatin; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms VENUS-2
  • Most Recent Events

    • 23 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 11 Jun 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 17 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top